ライフサイエンスコーパス: heart disease

1 ute myocardial infarction and fatal coronary heart disease).

2 from progression of long-standing underlying heart disease.

3 for ischemia and had no signs of structural heart disease.

4 ve strategy in patients with stable ischemic heart disease.

5 myocyte and novel therapeutic strategies for heart disease.

6 o the etiology and treatments for congenital heart disease.

7 netic etiologies of structural and myopathic heart disease.

8 workup and therapeutic guidance in ischemic heart disease.

9 he 7,529,481 cancer patients studied died of heart disease.

10 inical outcomes in patients with nonischemic heart disease.

11 portunity to address the burden of rheumatic heart disease.

12 already claims ~60% of the global burden of heart disease.

13 ardiopulmonary bypass surgery for congenital heart disease.

14 fe-threatening diseases, including rheumatic heart disease.

15 lity and genetic risk factors for congenital heart disease.

16 erapeutic potential of AC modRNA in ischemic heart disease.

17 isk stratification in patients with advanced heart disease.

18 nsient ischemic attack and no known coronary heart disease.

19 13-diHOME in a cohort of human patients with heart disease.

20 n populations are mostly limited to coronary heart disease.

21 nd unmarried are at a greatest risk of fatal heart disease.

22 to be targeted to develop new therapies for heart disease.

23 onic tricuspid regurgitation due to acquired heart disease.

24 undergoing evaluation for possible ischemic heart disease.

25 /incidence data for each NCD except ischemic heart disease.

26 rful diagnostic and prognostic biomarkers of heart disease.

27 are valuable for understanding hypertensive heart disease.

28 n performed in patients with stable ischemic heart disease.

29 ention, diagnosis and treatment of ischaemic heart disease.

30 ggests the presence of associated structural heart disease.

31 e biomarker to evaluate severity of diabetic heart disease.

32 ocioeconomic groups for stroke and ischaemic heart disease.

33 -stage liver disease in the absence of prior heart disease.

34 ions for diagnosis and treatment of valvular heart disease.

35 nslation of cardiomyocyte cell therapies for heart disease.

36 ich in turn can determine the progression of heart disease.

37 ions for diagnosis and treatment of valvular heart disease.

38 tioning, diabetes, hypertension, or coronary heart disease.

39 was modified by age, sex, and prior ischemic heart disease.

40 ay a key role in the development of Coronary Heart Disease.

41 biological processes that underlie metabolic heart disease.

42 ghts into cell-type-targeted intervention of heart diseases.

43 ure, valvular heart diseases, and congenital heart diseases.

44 such as neurodegenerative disorders and many heart diseases.

45 e in the development and progression of many heart diseases.

46 may serve as risk factors for human coronary heart diseases.

47 in months) was HF 11.7 (11.6-11.8), ischemic heart disease 1.6 (1.5-1.7), stroke 6.4 (6.3-6.5), chron

48 ular disease (1.09, 1.04-1.14) and ischaemic heart disease (1.10, 1.09-1.11); and low birthweight (1.

49 ive-year risk ratios were lower for ischemic heart disease (1.3 [1.3-1.4]), stroke (2.2 [2.1-2.2]), c

50 gery; 15.6 (95% CI 9.57-25.4) for congenital heart disease; 1.74 (95% CI 1.33-2.29) for diabetes mell

51 n between the presence of ECs and structural heart disease (15.3% in patients without ECs versus 36.5

52 us coronary intervention for stable ischemic heart disease, 1550, 2776, and 6661 received BMS, DES1,

53 4%), valvular heart disease (8%), congenital heart disease (2%), hypertrophic cardiomyopathy (2%), an

54 ally between 1990 and 2017 were for ischemic heart disease (3.2 million) and stroke (2.2 million).

55 Among females in 2016, heart disease (3.24 years), cancer (2.36 years), and uni

56 Findings revealed that heart disease (4.14 years), homicide (2.43 years), and c

57 both haematological cancer(2-4) and coronary heart disease(5)-this phenomenon is termed clonal haemat

58 (ARVD, 17%), postmyocarditis (14%), valvular heart disease (8%), congenital heart disease (2%), hyper

59 women, 23.4% were Black, 53.5% had ischemic heart disease, 87.7% had symptomatic heart failure, and

60 s (myocardial infarction plus fatal ischemic heart disease), 8849 and 10,922 ischemic strokes, and 24

61 l health care spending in 2016 were ischemic heart disease ($89.3 billion [95% CI, $81.1-$95.5 billio

62 Nearly 90% of patients with adult congenital heart disease (ACHD) die after the age of 40 years, and

63 aroxaban) for patients with chronic ischemic heart disease, acute coronary syndromes, and those under

64 es, inflammatory bowel disease, and coronary heart disease, all of which have available early interve

65 ics of type 2 diabetes mellitus and coronary heart disease already faced by South Asian countries, re

66 llution exposure has been linked to coronary heart disease, although evidence on PM2.5 and myocardial

67 disproportionately higher rates of coronary heart disease among American Indians and Alaska Natives

68 aki disease is the leading cause of acquired heart disease among children in the USA.

69 iated with a lower risk of incident coronary heart disease among participants with the Hp2-2 phenotyp

70 mortality, and higher incidence of ischemic heart disease among PLWHIV in cohort studies) outcomes s

71 events (including 609 incidents of coronary heart disease and 270 strokes).

72 Structural heart disease and a patent foramen ovale are strongly as

73 mass is a prognostic biomarker for incident heart disease and all-cause mortality.

74 Coronary heart disease and asthma or chronic obstructive pulmonar

75 s multiscale studies in models of congenital heart disease and beyond.

76 Heart disease and cancer contributed most at ages 55-69,

77 Heart disease and cancer contributed most at ages 55-69;

78 atient assigned riluzole died from ischaemic heart disease and coronary artery thrombosis, and one pa

79 management of patients with stable coronary heart disease and discuss implications for the evaluatio

80 tions for various diseases (such as coronary heart disease and heart attack) and many beta-adrenocept

81 In UK Biobank, a combination of coronary heart disease and heart failure in addition to T2D had t

82 erous cardiac conditions, including coronary heart disease and heart failure-the 2 most common substr

83 iac remodelling, and the resulting ischaemic heart disease and heart failure.

84 , the most common drivers of HF are ischemic heart disease and hypertension.

85 tral regurgitation (MR) is a common valvular heart disease and is the second most frequent indication

86 trial fibrillation (AF), two common forms of heart disease and leading contributors to morbidity and

87 in ambulatory patients with stable coronary heart disease and may merit routine use.

88 l events among patients with stable ischemic heart disease and moderate or severe ischemia.

89 with Kawasaki disease, leading to ischaemic heart disease and myocardial infarction.

90 However, mortality due to ischemic heart disease and other somatic diseases decreased for t

91 raffic noise increases the risk for ischemic heart disease and potentially other cardiometabolic dise

92 idelines recommend evaluation for underlying heart disease and reversible conditions for patients wit

93 586 participants without previous ischaemic heart disease and stroke at recruitment were included, o

94 ly monitors and evaluates sources of data on heart disease and stroke in the United States to provide

95 sease Control and Prevention, and the annual Heart Disease and Stroke Statistics report from the Amer

96 ta, Cochrane Library reviews, and the annual Heart Disease and Stroke Statistics report from the Amer

97 date focuses on a different topic related to heart disease and stroke statistics.

98 al arms, especially with respect to coronary heart disease and stroke subtypes.

99 associated with polygenic risk for coronary heart disease and type 2 diabetes.

100 ually by 3.6% for stroke, 5.4% for ischaemic heart disease, and 4.2% for any cause, between 2009 and

101 arget to improve symptoms in obesity-related heart disease, and a fascinating modifiable pathway invo

102 nd mean length of stay for stroke, ischaemic heart disease, and any cause in all relevant individuals

103 by around 2% annually for stroke, ischaemic heart disease, and any cause, but decreased to a greater

104 stablishing best practices in TAVR, valvular heart disease, and cardiovascular implantable electrical

105 ate disease risk, including type 2 diabetes, heart disease, and certain cancers.

106 ded clinical preventive services for cancer, heart disease, and diabetes.

107 healthy fetuses and fetuses with congenital heart disease, and it selectively increased cerebral blo

108 novel therapeutic procedures for structural heart disease, and represents a promising advance toward

109 heart failure, atrial fibrillation, coronary heart disease, and stroke) with subsequent risk of ESKD

110 (TOF) is the most common cyanotic congenital heart disease, and sudden cardiac death represents an im

111 n the gut can accelerate atherosclerosis and heart disease, and these TMA-producing enzymes are there

112 metrics like time-to-death, time-to-coronary heart disease, and time-to-cancer.

113 pretransition forms of HF such as rheumatic heart disease, and underdevelopment of healthcare system

114 Rhythm Disorders & Thromboembolism, Valvular Heart Disease, and Vascular Medicine (1-100).

115 Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases.

116 omorbid conditions of HF (including ischemic heart disease, aortic valve disease, atrial fibrillation

117 or sustained VA and the extent of functional heart disease are not associated with subsequent LTVA ev

118 r clinicians to diagnose and manage valvular heart disease as well as supporting documentation to enc

119 ive tissue effects including circulatory and heart disease, as well as potential immune system decrem

120 cation improvements for early-onset coronary heart disease, atrial fibrillation and prostate cancer.

121 terval, 8.38 to 15.50), followed by coronary heart disease, atrial fibrillation, and stroke.

122 women with unoperated and operated rheumatic heart disease before, during, and after pregnancy is a s

123 ed for cardiac CT for evaluation of ischemic heart disease between September 2014 and March 2016.

124 ons (74 313 for stroke, 69 446 for ischaemic heart disease) between 2009 and 2016.

125 rst-line test for the assessment of valvular heart disease, but cardiovascular magnetic resonance ima

126 case fatality rates for stroke and ischaemic heart disease, but greater reductions in case fatality r

127 s associated with increased risk of coronary heart disease, but its relevance for stroke types remain

128 spid regurgitation in adults with congenital heart disease, but the prevalence and prognostic implica

129 gy of a broad spectrum of diseases including heart disease, cancer, neurodegenerative diseases, and t

130 Diabetes, Alzheimer disease, and heart disease caused the most non-COVID-19 excess deaths

131 sis (AVS), which is the most common valvular heart disease, causes a progressive narrowing of the aor

132 eart syndrome (HLHS) is a complex congenital heart disease characterized by abnormalities in the left

133 While comorbidity between coronary heart disease (CHD) and depression is evident, it is unc

134 rumented blood sucrose with risk of coronary heart disease (CHD) and its risk factors (i.e., type 2 d

135 isease (ASCVD) events, inclusive of coronary heart disease (CHD) and stroke, and is a decision-making

136 se polygenic risk scores (PRSs) for coronary heart disease (CHD) are derived from mainly European anc

137 (Lp[a]) and family history (FHx) of coronary heart disease (CHD) are individually associated with car

138 incident CVD cases, including 9,794 coronary heart disease (CHD) cases and 6,174 strokes.

139 Patients with congenital heart disease (CHD) comprised 57% of the cohort.

140 Rates for recurrent coronary heart disease (CHD) events have declined in the United S

141 dividually associated with incident coronary heart disease (CHD) events.

142 s10911021) has been associated with coronary heart disease (CHD) in type 2 diabetes.

143 s of long-term changes in TMAO with coronary heart disease (CHD) incidence.

144 Congenital heart disease (CHD) is associated with abnormal brain de

145 brain development in fetuses with congenital heart disease (CHD) may result from inadequate cerebral

146 patients with PAD versus those with coronary heart disease (CHD) or cerebrovascular disease.

147 le-blind, controlled trial in 1,002 coronary heart disease (CHD) patients, whose primary objective is

148 ased myocardial infarction (MI) and coronary heart disease (CHD) risks (MI odds ratio (OR) = 1.24, 95

149 could be useful for population-wide coronary heart disease (CHD) screening.

150 ower age-specific rates of incident coronary heart disease (CHD) than men.

151 of neuropsychiatric disorders and congenital heart disease (CHD) which use de novo mutations (DNMs) f

152 nts, such as those with established coronary heart disease (CHD), are lacking.

153 iodontal disease has been linked to coronary heart disease (CHD), but studies have been inconclusive.

154 eractions at 13 variants, including coronary heart disease (CHD), CKD, PAD and neuropathy.

155 +MPA) resulted in increased risk of coronary heart disease (CHD), whereas oral conjugated equine estr

156 iple congenital defects including congenital heart disease (CHD).

157 uces HDLs; and may increase risk of coronary heart disease (CHD).

158 mellitus is a major risk factor for coronary heart disease (CHD).

159 nal brain volumes in infants with congenital heart disease (CHD).

160 irculating lipoprotein lipids cause coronary heart disease (CHD).

161 riptional regulators causes human congenital heart disease (CHD); however, the underlying CHD gene re

162 e of a modern lifestyle in abetting Coronary Heart Diseases (CHD) have mostly focused on deterrent he

163 Congenital heart diseases (CHDs), including hypoplastic left heart

164 rs (early and late preterm birth, congenital heart disease, chronic lung disease, intensive care unit

165 014 and (2) the Give Us a Clue to Cancer and Heart Disease (CLUE) II cohort (baseline 1989).

166 ify cancer patients at highest risk of fatal heart disease compared to the general population and oth

167 These include the evaluation of structural heart diseases, congenital heart diseases, peri-procedur

168 The underlying structural heart disease consisted of dilated cardiomyopathy (DCM,

169 The global burden of rheumatic heart disease continues to be significant although it is

170 As loss of contractile function in heart disease could often be mitigated by increased card

171 Patient phenotypes include congenital heart disease, craniofacial malformations, and neurodeve

172 used to determine hazard ratios for coronary heart disease, CVD, and all-cause mortality according to

173 tratified analysis, the increase in coronary heart disease, CVD, and all-cause mortality in obese ind

174 a higher risk of CAC and subsequent coronary heart disease, CVD, and all-cause mortality.

175 izations, myocardial infarction, stroke, and heart disease death, and all-cause mortality.

176 , 118 myocardial infarctions, 45 strokes, 96 heart disease deaths, and 351 deaths from all causes in

177 ble for multifactorial complex diseases like heart disease, diabetes and cancer.

178 for noncancer causes of death were those for heart disease (EAR, 15.1; SMR, 2.1), infections (EAR, 10

179 7.4; SMR, 5.0) after advanced-stage cHL and heart disease (EAR, 6.6; SMR, 1.7), ILD (EAR, 3.7; SMR,

180 ian populations including premature coronary heart disease, early type 2 diabetes mellitus, ubiquitou

181 inic Bipolar Disorder, and Quebec Congenital Heart Disease EHR datasets.

182 Heart disease (especially myocardial infarction (MI)) an

183 n-source epidemic, such as diet and coronary heart disease, especially in populations with readily av

184 nt and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapi

185 nt and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapi

186 ization, or death from CVD; n=431), coronary heart disease events (MI or death from coronary heart di

187 , is associated with a reduction in coronary heart disease events and death.

188 score was associated with incident coronary heart disease events but did not significantly improve d

189 rdiorespiratory fitness and reduced coronary heart disease events.

190 Ischaemic heart disease evokes a complex immune response.

191 Prenatal detection of congenital heart disease facilitates the opportunity for potentiall

192 standard of care for patients with valvular heart disease for many decades, but transcatheter heart

193 ients with atrial fibrillation and rheumatic heart disease, for the treatment of patients with recent

194 g as part of the CHD GENES study (Congenital Heart Disease Genetic Network).

195 This executive summary of the valvular heart disease guideline provides recommendations for cli

196 ny recommendations from the earlier valvular heart disease guidelines have been updated with new evid

197 ny recommendations from the earlier valvular heart disease guidelines have been updated with new evid

198 companion document on advocacy for rheumatic heart disease has been developed.

199 c hypertrophy whose therapeutic targeting in heart disease has been elusive due to its role in other

200 ions to 3 cardiovascular endpoints (coronary heart disease, heart failure, and atrial fibrillation).

201 tain cardiovascular diseases (e.g., coronary heart disease, heart failure, and atrial fibrillation).

202 n to identify signs and symptoms of ischemic heart disease, heart failure, and severe valvular diseas

203 itations; and diagnoses of diabetes, stroke, heart disease, heart failure, cancer, chronic bronchitis

204 for patients with new-onset stroke, coronary heart disease, heart failure, peripheral arterial diseas

205 rders, subclinical atherosclerosis, coronary heart disease, heart failure, valvular disease, venous d

206 interoception in patients with hypertensive heart disease (HHD).

207 deprivation and self-reported hypertension, heart disease, hypercholesterolaemia and diabetes).

208 scular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of

209 However, their long-term risks of ischemic heart disease (IHD) and whether such risks are due to sh

210 ajor coronary events (MCEs), 37,992 ischemic heart disease (IHD), and 42,951 strokes were recorded.

211 revious myocardial infarction (MI), ischemic heart disease (IHD), heart failure (HF), atrial fibrilla

212 olesterolemia (FH) in subjects with ischemic heart disease (IHD), premature IHD, and severe hyperchol

213 As) are a well-known risk factor of ischemic heart disease (IHD).

214 roportionate excess of deaths as a result of heart disease, ILD, infections, AEs, and solid tumors.

215 loid that has been used for the treatment of heart disease, impotency, and psychosis) was found to be

216 ) is the leading cause of childhood acquired heart disease in developed nations and can result in cor

217 s Cohort Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA) from 1,389 participa

218 nd Swiss Study on Air Pollution and Lung and Heart Diseases in Adults: n = 2,610, aged 36-82 years) f

219 is associated with CVD, especially coronary heart disease, in the setting of hyperglycemia.

220 ociety of Cardiology guidelines for valvular heart disease included changes in the definition of seve

221 most all cancer survivors, the risk of fatal heart disease increases with time.

222 ell (iPSC) disease model of a common form of heart disease involving the aortic valve (AV).

223 standardized mortality ratio (SMR) of fatal heart disease is 2.24 (95% CI: 2.23-2.25).

224 Coronary heart disease is a chronic, systemic disease with a wide

225 Ischemic heart disease is a leading cause of heart failure and de

226 Valvular heart disease is a major cause of morbidity and mortalit

227 zation improves prognosis in stable ischemic heart disease is controversial.

228 Valvular heart disease is observed in approximately 2% of the gen

229 Awareness that heart disease is the LCOD among women declined from 2009

230 with incident HF, HF subtypes, or structural heart disease is unknown.

231 ing RV hypertrophy and failure in congenital heart disease is unknown.

232 improve health outcomes among patients with heart disease, its use has been suboptimal.

233 s linked to chronic health problems, such as heart disease, kidney disease, high blood pressure, diab

234 chronic kidney disease, presence of valvular heart disease, left ventricular ejection fraction phenot

235 verse clinical outcome, particularly in left heart disease (LHD) patients.

236 vascular care for the management of ischemic heart disease may not be infected with this novel corona

237 e centriole with implications for congenital heart disease mechanisms.

238 on level, hyperlipidemia, diabetes, coronary heart disease, migraine, hypotension, and obstructive sl

239 rategy) in participants with stable ischemic heart disease, moderate or severe ischemia, and advanced

240 imary cardiomyocytes from human infants with heart disease, modifying LMNB2 expression correspondingl

241 (Mb) deletion from LCR22A-D have congenital heart disease, mostly of the conotruncal type (CTD), whe

242 was associated with younger age, congenital heart disease, multiple AP, AP location (right sided and

243 luded arrhythmia (n = 88, 28.8%), congenital heart disease (n = 72, 23.5%), and cardiomyopathy (n = 7

244 =1269; atrial fibrillation, n=1337; coronary heart disease, n=696; and stroke, n=559) and 210 cases o

245 rt disease events (MI or death from coronary heart disease; (n=277), stroke (n=68), HF events (HF hos

246 ith multivessel disease and stable ischaemic heart disease, non-ST-segment elevation acute coronary s

247 amples from 5 individuals without structural heart disease or AF.

248 diovascular disease cohorts where structural heart disease or ischemia may influence repolarization d

249 -11.6 years; 88 men) with suspected ischemic heart disease or known coronary disease who had clinical

250 tients with recommended indications, such as heart disease or migraine.

251 ses as well as screened for SUDEP, epilepsy, heart disease or respiratory disease-related genes from

252 to show a significant reduction in coronary heart disease or total mortality to the design of the tr

253 sm (OR 1.22, 95% CI 1.12-1.34) and ischaemic heart disease (OR 1.30, 95% CI 1.15-1.47).

254 onary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, va

255 iseases, such as cancer, but also arthritis, heart diseases, or pulmonary fibrosis.

256 nts are enriched in patients with congenital heart disease, particularly those with extra-cardiac ano

257 apy (CRT) studies in pediatric or congenital heart disease patients have shown an improvement in ejec

258 In pediatric and congenital heart disease patients with symptomatic systolic heart f

259 nt-free survival in pediatric and congenital heart disease patients, using a propensity score-matched

260 propriate and timely treatment of structural heart disease patients; 2) to minimize the risk of COVID

261 eight, a higher blood pressure, a history of heart disease, performance of less physical activity, an

262 ion of structural heart diseases, congenital heart diseases, peri-procedural electrophysiology applic

263 and the presence of a cough, COPD, ischemic heart disease, pregnancy-related mortality, maternal sep

264 , left atrium area, hypertension, structural heart disease, presence of left common trunk, patent for

265 Ischemic heart disease prevalence increased for all to 2006 befor

266 These three genes were previously related to heart disease, providing support to the hypothesis that

267 ociations with obesity, type 2 diabetes, and heart disease (r(g) ~ 0.15-0.5).

268 Patients with stable ischemic heart disease remain at substantial risk for long-term M

269 Ischemic heart disease remains the foremost cause of death global

270 cohorts (with high income, cancer, and with heart disease, respectively).

271 Rheumatic heart disease (RHD) affects ~40 million people and claim

272 Rheumatic heart disease (RHD) is a complication of group A strepto

273 Rheumatic heart disease (RHD), an autoinflammatory heart disease,

274 ase conditions (including stroke, congenital heart disease, rhythm disorders, subclinical atheroscler

275 of 257 nutrients and 117 foods with coronary heart disease risk (acute myocardial infarction and fata

276 (MT) contributes to the increase in coronary heart disease risk.

277 ciations of specific nutrients with coronary heart disease risk.

278 about tobacco exposure to assess cancer and heart disease risk.

279 In patients with stable ischemic heart disease, routine revascularization was not associa

280 ter menopause and typically develop coronary heart disease several years later than men.

281 measurement in patients with stable ischemic heart disease (SIHD) are uncertain, as prior studies hav

282 The heart disease-specific mortality rate is 10.61/10,000-pe

283 on the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors,

284 easures of cardiometabolic disease (coronary heart disease, stroke, and type 2 diabetes) from the fir

285 outcome was a composite of nonfatal coronary heart disease, stroke, transient ischemic attack, heart

286 rse outcomes compared to whites while facing heart diseases, stroke, cancer, asthma, influenza and pn

287 In patients with complex congenital heart disease, such as those with tetralogy of Fallot, t

288 nal mortality is high in women with acquired heart disease that presents during pregnancy (such as ac

289 appropriate recipient selection for advanced heart disease therapies including heart transplantation

290 cardiovascular pathology, such as congenital heart disease, timely counselling is possible and the ou

291 actors to test genome-wide PRSs for coronary heart disease, type 2 diabetes, atrial fibrillation, bre

292 In patients with congenital heart disease undergoing open-heart surgery, de novo var

293 s score <3 and without a history of ischemic heart disease), valvular, and end-organ disease were fol

294 lve disease, atrial fibrillation, congenital heart disease, various cardiomyopathies, obesity, hypert

295 We showed family history of heart disease was associated with a 20% increase in depr

296 so proposed an alternative: whether coronary heart disease was preventable at all by simultaneous int

297 ed cohort of 1,315 pregnancies in women with heart disease was studied.

298 tic heart disease (RHD), an autoinflammatory heart disease, was recently declared a global health pri

299 cardiac events (SCEs) in pregnant women with heart disease, whether they were preventable, and their

300 We studied 2517 patients with congenital heart disease who had undergone whole-exome sequencing a